156 related articles for article (PubMed ID: 38273242)
1. A gadoxetic acid-enhanced MRI-based model using LI-RADS v2018 features for preoperatively predicting Ki-67 expression in hepatocellular carcinoma.
Liang Y; Xu F; Mou Q; Wang Z; Xiao C; Zhou T; Zhang N; Yang J; Wu H
BMC Med Imaging; 2024 Jan; 24(1):27. PubMed ID: 38273242
[TBL] [Abstract][Full Text] [Related]
2. Liver imaging reporting and data system diagnostic performance in hepatocellular carcinoma when modifying the definition of "washout" on gadoxetic acid-enhanced magnetic resonance imaging.
Hu W; Lyu R; Wang D; Gao Z; Sun C; Jia K
Arab J Gastroenterol; 2024 Feb; 25(1):58-63. PubMed ID: 38245474
[TBL] [Abstract][Full Text] [Related]
3. A gadoxetic acid-enhanced MRI-based multivariable model using LI-RADS v2018 and other imaging features for preoperative prediction of macrotrabecular-massive hepatocellular carcinoma.
Liang Y; Xu F; Wang Z; Tan C; Zhang N; Wei X; Jiang X; Wu H
Eur J Radiol; 2022 Aug; 153():110356. PubMed ID: 35623312
[TBL] [Abstract][Full Text] [Related]
4. Suboptimal performance of LI-RADS v2018 on gadoxetic acid-enhanced MRI for detecting hepatocellular carcinoma in liver transplant candidates.
Oh NE; Choi SH; Kim S; Lee H; Jang HJ; Byun JH; Won HJ; Shin YM
Eur Radiol; 2024 Jan; 34(1):465-474. PubMed ID: 37532900
[TBL] [Abstract][Full Text] [Related]
5. A multivariate model based on gadoxetic acid-enhanced MRI using Li-RADS v2018 and other imaging features for preoperative prediction of dual‑phenotype hepatocellular carcinoma.
Liu MT; Zhang JY; Xu L; Qu Q; Lu MT; Jiang JF; Zhao XC; Zhang XQ; Zhang T
Radiol Med; 2023 Nov; 128(11):1333-1346. PubMed ID: 37740839
[TBL] [Abstract][Full Text] [Related]
6. Optimizing CT and MRI criteria for differentiating intrahepatic mass-forming cholangiocarcinoma and hepatocellular carcinoma.
Wu H; Liang Y; Wang Z; Tan C; Yang R; Wei X; Jiang X
Acta Radiol; 2023 Mar; 64(3):926-935. PubMed ID: 35898164
[TBL] [Abstract][Full Text] [Related]
7. The role of gadoxetic acid-enhanced MRI features for predicting microvascular invasion in patients with hepatocellular carcinoma.
Yang H; Han P; Huang M; Yue X; Wu L; Li X; Fan W; Li Q; Ma G; Lei P
Abdom Radiol (NY); 2022 Mar; 47(3):948-956. PubMed ID: 34962593
[TBL] [Abstract][Full Text] [Related]
8. Targetoid hepatic observations on gadoxetic acid-enhanced MRI using LI-RADS version 2018: emphasis on hepatocellular carcinomas assigned to the LR-M category.
Park HJ; Kim YK; Cha DI; Ko SE; Kim S; Lee ES; Ahn S
Clin Radiol; 2020 Jun; 75(6):478.e13-478.e23. PubMed ID: 32033745
[TBL] [Abstract][Full Text] [Related]
9. Liver imaging reporting and data system (LI-RADS) v2018: comparison between computed tomography and gadoxetic acid-enhanced magnetic resonance imaging.
Nakao S; Tanabe M; Okada M; Furukawa M; Iida E; Miyoshi K; Matsunaga N; Ito K
Jpn J Radiol; 2019 Sep; 37(9):651-659. PubMed ID: 31321619
[TBL] [Abstract][Full Text] [Related]
10. LI-RADS M (LR-M) criteria and reporting algorithm of v2018: diagnostic values in the assessment of primary liver cancers on gadoxetic acid-enhanced MRI.
Kim MY; Joo I; Kang HJ; Bae JS; Jeon SK; Lee JM
Abdom Radiol (NY); 2020 Aug; 45(8):2440-2448. PubMed ID: 32382817
[TBL] [Abstract][Full Text] [Related]
11. Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?
Xie S; Zhang Y; Chen J; Jiang T; Liu W; Rong D; Sun L; Zhang L; He B; Wang J
Abdom Radiol (NY); 2022 Feb; 47(2):596-607. PubMed ID: 34773467
[TBL] [Abstract][Full Text] [Related]
12. Comparison of CT and gadoxetic acid-enhanced MRI with liver imaging reporting and data system to assess liver tumors before resection.
Chen MF; Ho MC; Kao JH; Hwang RM; Deng SB; Yen KC; Liang PC; Wu CH
J Formos Med Assoc; 2024 Mar; 123(3):318-324. PubMed ID: 38044205
[TBL] [Abstract][Full Text] [Related]
13. LI-RADS Version 2018 Targetoid Appearances on Gadoxetic Acid-Enhanced MRI: Interobserver Agreement and Diagnostic Performance for the Differentiation of HCC and Non-HCC Malignancy.
Min JH; Lee MW; Park HS; Lee DH; Park HJ; Lee JE; Park SJ; Kim SS; Park SH; Ha SY; Hwang JA; Cha DI; Park B
AJR Am J Roentgenol; 2022 Sep; 219(3):421-432. PubMed ID: 35319906
[No Abstract] [Full Text] [Related]
14. LI-RADS v2014 categorization of hepatocellular carcinoma: Intraindividual comparison between gadopentetate dimeglumine-enhanced MRI and gadoxetic acid-enhanced MRI.
Song JS; Choi EJ; Hwang SB; Hwang HP; Choi H
Eur Radiol; 2019 Jan; 29(1):401-410. PubMed ID: 29922928
[TBL] [Abstract][Full Text] [Related]
15. Radiomic analysis of Gd-EOB-DTPA-enhanced MRI predicts Ki-67 expression in hepatocellular carcinoma.
Fan Y; Yu Y; Wang X; Hu M; Hu C
BMC Med Imaging; 2021 Jun; 21(1):100. PubMed ID: 34130644
[TBL] [Abstract][Full Text] [Related]
16. Performance of adding hepatobiliary phase image in magnetic resonance imaging for detection of hepatocellular carcinoma: a meta-analysis.
Pan J; Li W; Gu L; Liu C; Zhang K; Hong G
Eur Radiol; 2022 Nov; 32(11):7883-7895. PubMed ID: 35579711
[TBL] [Abstract][Full Text] [Related]
17. The role of lesion hypointensity on gadobenate dimeglumine-enhanced hepatobiliary phase MRI as an additional major imaging feature for HCC classification using LI-RADS v2018 criteria.
Zhang Y; Tang W; Xie S; Chen J; Zhang L; Rong D; Kuang S; He B; Wang J
Eur Radiol; 2021 Oct; 31(10):7715-7724. PubMed ID: 33782766
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the diagnostic performance of the 2017 and 2018 versions of LI-RADS for hepatocellular carcinoma on gadoxetic acid enhanced MRI.
Ko A; Park HJ; Lee ES; Park SB; Kim YK; Choi SY; Ahn S
Clin Radiol; 2020 Apr; 75(4):319.e1-319.e9. PubMed ID: 31858990
[TBL] [Abstract][Full Text] [Related]
19. Hepatocellular carcinoma detection in liver cirrhosis: diagnostic performance of contrast-enhanced CT vs. MRI with extracellular contrast vs. gadoxetic acid.
Semaan S; Vietti Violi N; Lewis S; Chatterji M; Song C; Besa C; Babb JS; Fiel MI; Schwartz M; Thung S; Sirlin CB; Taouli B
Eur Radiol; 2020 Feb; 30(2):1020-1030. PubMed ID: 31673837
[TBL] [Abstract][Full Text] [Related]
20. A modified LI-RADS: targetoid tumors with enhancing capsule can be diagnosed as HCC instead of LR-M lesions.
Min JH; Kim JM; Kim YK; Kim H; Choi GS; Kang TW; Cha D; Hwang JA; Ko SE; Ahn S
Eur Radiol; 2022 Feb; 32(2):912-922. PubMed ID: 34345947
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
